Nervous Disorder TRIZ Cases

HJ8 and HJ9 antibodies bind tau to inhibit aggregation spread, reducing cognitive decline in Alzheimer's disease.

Engineered gene regulatory elements drive therapeutic protein expression in nociceptors via adeno-associated virus vectors.

Direct intracerebroventricular enzyme administration bypasses the blood-brain barrier to treat central nervous system symptoms in Hunter syndrome.

Filler sequences adjust vector genome length to match capsid limits, reducing encapsidated impurities and enhancing therapeutic safety.

Administering nitroxide antioxidants to modulate HSP90 gene expression levels in human subjects.

Peptides targeting sushi domain 1 of GABABR1a improve selectivity while maintaining binding affinity.

Tau-specific antibodies remove hyperphosphorylated tau protein, addressing excitotoxicity without affecting normal neuronal function.

Beta-cyclodextrin extracts cholesterol from ruminant dairy fat, resolving the trade-off between nutritional safety and manufacturing complexity.

Combining omega-3 fatty acids with folate and vitamin B12 to treat cognitive impairment.

Inhibitors bind nitrated amyloid-beta regions to prevent aggregation, addressing ineffective existing treatments.

Detecting VMAT1 gene polymorphisms identifies genetic susceptibility to mood disorders and schizophrenia.

Thiolated hydrogel depots release brain-derived neurotrophic factor locally, bypassing the blood-brain barrier to improve motor recovery after stroke.

κ-CPTx-bt104 polypeptide inhibits potassium ion channel currents via specific binding to the pore region.

Live non-pathogenic fecal bacteria and sterile filtrate compositions administered orally to treat multiple sclerosis.

A Tmem100 mutant peptide blocks acute and chronic pain by inhibiting TRPA1 channel activity.

Composite liposomes with cardiolipin and phosphatidic acid bind amyloid-beta peptides, achieving dramatic plaque reduction without immune system toxicity.

Oral dipeptides LH, DV, and MH suppress microglial inflammation, replacing invasive injections to enable continuous treatment for stress-related conditions.

Systematic parameter changes identify stable polymorphs of ponesimod salts, resolving complexity in predicting solid forms to improve therapeutic efficacy.

A beta-solenoid scaffold projects disease-associated epitopes to mimic prion conformers and elicit targeted antibodies.

A galacto-rhamnogalacturonate compound reduces inducible nitric oxide synthase expression in affected tissues.

Human binding molecules target tau paired helical filaments to inhibit aggregation spreading.

Amino protecting agents enable amine substitution on isoquinoline rings, preventing side reactions and improving yield under mild conditions.

Allosteric ISVDs regulate LRRK2 kinase activity without disrupting subcellular localization, avoiding kidney and lung toxicity from ATP-competitive inhibitors.

Diaryl boron compounds selectively trap the oxidized form of type IIa RPTPs, resolving specificity challenges caused by high amino acid sequence similarity.

Fully human antibodies bind endothelial cell receptors to trigger receptor-mediated transcytosis for targeted drug delivery.

Propylene glycol dissolves lamotrigine into stable non-aqueous solutions, eliminating tablet crushing and dosage variability for pediatric patients.

Oral Phe-Pro peptide increases acetylcholine release, avoiding hepatotoxicity from traditional inhibitors.

A postbiotic composition uses probiotic lysates to treat psychiatric disorders without live microorganisms.

Histidine-acetate coated copper nanoclusters cross the blood-brain barrier to treat Menkes syndrome neurological deficits.

Combining mineralocorticoid and angiotensin receptor antagonists lowers blood pressure effectively.

Segmenting the SORL1 gene creates a mini-receptor that overcomes vector size limits to treat Alzheimer's.

Dihydrobenzoxathiazepine derivatives activate AMPA receptors to enhance neuronal excitability and glutamatergic neurotransmission.

Thrombin-treated stem cell-derived exosomes inhibit nerve cell death and reduce inflammatory cytokine levels in brain tissue.

Humanized antibodies recognize the pS409 phosphoepitope on pathological tau conformers, resolving specificity and efficacy trade-offs in Alzheimer's treatment.

Protamine converts inhibitory CSPGs into permissive signals via RPTPσ binding, enabling axon regeneration in CNS injuries.

Activity-dependent promoters restrict gene therapy to hyperactive neurons, eliminating off-target effects on bystander cells.

Recombinant cells expressing bifunctional desaturases and elongases convert precursors into EPA, DPA, and DHA with high efficiency.

Combining D-limonene with melatonin targets sleep pressure and circadian rhythms to improve sleep quality without sedative side effects.

Isolating this fungal enzyme resolves low activity and narrow condition limits by providing high catalytic efficiency with broad thermal and pH tolerance.

Humanized anti-interleukin-18 antibodies with specific CDRs neutralize IL-18, reducing Th1 cell proliferation in autoimmune diseases.

Fusion protein combines CETP B-cell epitopes with an Fc fragment to overcome low immunogenicity and selectively inhibit plasma CETP.

A glucagon-derived peptide derivative acts as a dual agonist for glucagon and GLP-1 receptors to drive energy metabolism.

Adeno-associated viral vectors transfer the GLA transgene to establish endogenous enzyme production, reducing toxic substrate accumulation in nervous tissues.

A polymeric conjugate couples opioid haptens to immune agonists to activate B cells and induce durable antibody responses.

Aprepitant targets neurokinin 1 receptors to reduce amyloid plaques and cognitive decline without toxic side effects.

Ursolic acid in rosemary extracts increases circadian protein expression levels, restoring rhythms disrupted by oxidative stress.

Human-derived monoclonal antibodies target poly-glycine-alanine dipeptide repeats to address instability and immunogenicity issues in RNA-based therapies.